Filing Flows › Health Care › Autolus Therapeutics (AUTL)
Autolus Therapeutics (AUTL) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Autolus Therapeutics (AUTL) Q2 2026 earnings results →
Q2 2026 Revenue up 118% year over year to $45.7M · 86¢ of every $1 of revenue lost · operating margin -95.9%
Autolus Therapeutics made $45.7M in Q2 2026 (+118% Y/Y): Product revenue, net $45.7M, License revenue $17K. Operating margin -95.9%, net loss $39.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $45.7M in Q2 2026, up 118% year over year and up 74% from the previous quarter. Product revenue, net was the largest line at 100% of revenue. Product revenue, net added $24.7M year over year (up 118%), 100% of the total change.
Operating costs exceeded revenue by $43.8M, an operating margin of -95.9%. Total costs grew 9% against revenue growth of 118%. The fastest-growing cost line was SG&A (+36%). The quarter ended with a net loss of $39.1M, narrower than the previous quarter's $71.6M loss.
Operating cash flow was −$25.1M. Non-cash charges added back $2.2M of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items added $7.3M. Capital expenditures of $913K exceeded it, leaving free cash flow of −$26.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $45.7M | +118% | -95.9% | −$39.1M | −$25.1M |
| Q1 2026 | 10-Q | May 14, 2026 | $26.2M | +192% | -227.0% | −$71.6M | −$65.3M |
| Q4 2025 | 10-K | Mar 27, 2026 | $24.3M | 838× | -298.3% | −$90.3M | −$67.3M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $21.2M | — | -337.9% | −$79.1M | −$67.9M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $20.9M | — | -292.6% | −$47.9M | −$72.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $9.0M | -11% | -726.3% | −$70.2M | −$75.6M |
| Q4 2024 | 10-K | Mar 20, 2025 | $29K | — | n/m | −$27.6M | −$37.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Autolus Therapeutics
We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.
In its own words, from its 10-K, filed Mar 27, 2026.
Autolus Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +118% against the peers' median +29%. Operating margin: -95.9% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AUTL Autolus Therapeutics | Q2 2026 | $45.7M | +118% | -95.9% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Autolus Therapeutics 10-Q on SEC EDGAR · CIK 1730463 · Biological Products, (No Diagnostic Substances)
13F: who owns AUTL and who is buying
More on AUTL
- How Autolus Therapeutics makes money: revenue by segment
- Autolus Therapeutics next earnings date and what analysts expect
- Autolus Therapeutics stock forecast, price target and fair value
- Who owns Autolus Therapeutics stock: holders, funds and Congress trades
- Autolus Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results